iRhythm Backed by Zio Despite Sharp Drop

iRhythm Technologies is drawing support after positive results around its Zio device, presented at the 2026 American College of Cardiology meeting. The data, drawn from thousands of patients, strengthen the clinical case for its cardiac monitoring offering and improve visibility on potential growth, helped by AI innovation and expanding prescriptions in primary care. However, the stock remains under pressure after falling about 31% since October, amid reimbursement pressures, rising competition, and an unresolved regulatory overhang with the DOJ. The name therefore remains mixed: stronger clinical fundamentals, but still elevated market risk in the near term.